Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Fanconi anemia group D2 protein (FANCD2) is a core component of the Fanconi anemia DNA repair pathway, which detects and repairs DNA interstrand cross-links—a particularly cytotoxic form of DNA damage. Upon DNA damage, FANCD2 forms a heterodimer with FANCI, and is subsequently monoubiquitinated by the Fanconi anemia (FA) core complex. This modification enables the complex to recruit downstream DNA repair factors to chromatin and coordinate repair, preserving genomic stability. Mutations in the FANCD2 gene cause Fanconi anemia (FA), characterized by progressive bone marrow failure and increased cancer risk. The term "opposite strand" does not refer to any recognized molecular entity and is likely an annotation artifact rather than a legitimate therapeutic target.
For the pathway: monoubiquitination of FANCD2 (and FANCI) initiates repair of DNA interstrand cross-links
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fanconi anemia group D2 protein (FANCD2).